Abstract 272P
Background
Epirubicin (EPI) is a first-line chemotherapeutic drug for the clinical treatment of diffuse large B cell lymphoma (DLBCL), but the overexpression of multidrug resistance (MDR) transporter proteins, such as P-glycoprotein (P-gp), renders EPI ineffective. On the basis of some studies, melatonin (MLT) is considered to possess the potential for chemotherapeutic synergy that can be leveraged to overcome MDR.
Methods
The human DLBCL cells SUDHL-6 and SUDHL-10 were incubated with MLT and/or EPI for 48 h. Using CCK8 assay, the cell viability of SUDHL-10 and SUDHL-6 cell lines under different treatments were tested. Using AO/EB assay ,the apoptosis of SUDHL-6 cell line was detected. Cytochrome c release experiment was used to reveal the further molecular mechanism. Immunofluorescence experiment was used to detect the expression of P-gp of DLBCL cell lines under different drug treatment groups. Rhodamine-123 and epirubicin accumulation test were used to detect the function of P-gp. Immunohistochemical staining studies in tumor tissue of DLBCL disclosed that the expression of P-gp and P65. Western blotting assay and pulldown assay were used to detect the relationship between NF-κB pathway and P-gp exression.
Results
Melatonin potentiated the epirubicin-mediated inhibition of cell proliferation and increased epirubicin-induced apoptosis. Melatonin inhibits epirubicin-induced P-glycoprotein expression and the activity of the P-glycoprotein pump.Epirubicin promotes the expression of P-gp by activating the NF-κB pathway. However, melatonin inhibited the epirubicin-mediated activation of NF-κB signaling and the expression of P-gp.
Conclusions
Our results demonstrated that MLT inactivating the NF-κB pathway and down-regulating the expression of P-gp, ultimately sensitized EPI-mediated growth suppression of DLBCL cells.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The second hospital of Dalian medical university.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
314P - An EGF motif of Del1 inhibits efficient angiogenesis and suppresses tumour growth in vivo
Presenter: Hisataka Kitano
Session: Poster display session
Resources:
Abstract
315P - Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab
Presenter: James Bonner
Session: Poster display session
Resources:
Abstract
316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
Presenter: Ezra Cohen
Session: Poster display session
Resources:
Abstract
322P - Three-year overall survival update from the PACIFIC trial
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
323P - Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort
Presenter: Yuan Li
Session: Poster display session
Resources:
Abstract
324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy
Presenter: Tsu Yi Chao
Session: Poster display session
Resources:
Abstract
325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
Presenter: Lawrence Wong
Session: Poster display session
Resources:
Abstract
326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies
Presenter: Esdy Rozali
Session: Poster display session
Resources:
Abstract
327P - Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution
Presenter: Xiaolong Liu
Session: Poster display session
Resources:
Abstract
328P - A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors
Presenter: Fumiko Hayashi
Session: Poster display session
Resources:
Abstract